Please assess the completion status of the following clinical trial:

Trial Title: P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients at least 1 year of age and weighing more than 10kg~* Microscopic diagnosis of Plasmodium species infection~* Negative P. falciparum malaria rapid diagnostic test (histidine rich protein 2)~* Fever (temperature 37.5°C) or history of fever in the last 48 hours~* Able to participate in the trial and comply with the clinical trial protocol~* Written informed consent to participate in trial; thumbprint is required for illiterate patients, and written consent from parents/guardian for children below age of consent~Exclusion Criteria:~* Clinical or laboratory criteria for severe malaria, including warning signs, requiring parenteral treatment according to modified WHO criteria (see Appendix 4)~* Parasitaemia \> 20,000 /μL (P. knowlesi)~* Inability to tolerate oral treatment~* Concomitant infection with any other malaria species~* Pregnancy or lactation~* Unable or unwilling to use contraception during study period~* Known hypersensitivity or allergy to artemisinin derivatives~* Serious underlying disease (cardiac, renal or hepatic)~* Received anti-malarials in last 2 months~* Previous psychiatric illness or epilepsy~* Previous episode of cerebral malaria

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate-mefloquine (Type: ACTIVE_COMPARATOR): 3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
- Chloroquine (Type: ACTIVE_COMPARATOR): 4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).